Her presentation included some key figures about the biosimilar market in France. Biosimilars turnover is growing very rapidly. It had been multiplied by 5.6 times over the past five years and it reached Euros 1.6 billion in 2021. More than half of turnover is generated by hospital (54%) and community pharmacies (46%). Biosimilars represent almost half (48%) of the biological market and a 3% of the total pharmaceutical market.

 
However, and despite these growing numbers, the penetration rate is quite low with 25% on average measured as volume share of drugs delivered in the community whether prescribed by hospital- or community-based practitioners, see Figure 1,. This is far from the objective of 80% that was to be achieved by 2023.

 
Figure 1: Heterogenous penetration rate (volume share, community)

In a series of the next two articles, the incentives and challenges of biosimilar medicines in France will be discussed.

Related articles
Challenges of biosimilar medicines in France 

Incentives promoting use of biosimilar medicines in France 

Competition from biosimilars drives price reductions for biologicals in France

The cost-effectiveness of biosimilars

Reference
1. Biosimilar medicines: changing patient care pathways, changing outcomes. Webinar BIOS 22. 28 April 2022, Thursday. Speaker: Nadia Amer, Health Economics Analyst, Health Product Department, Caisse Nationale d’Assurance Maladie (CNAM), France.

Permission granted to reproduce for personal and non-commercial use only. All other reproduction, copy or reprinting of all or part of any ‘Content’ found on this website is strictly prohibited without the prior consent of the publisher. Contact the publisher to obtain permission before redistributing.

Copyright – Unless otherwise stated all contents of this website are © 2022 Pro Pharma Communications International. All Rights Reserved.